Ligand spent most of the last decade shedding things. It spun off its antibody discovery unit in November 2022, sold assets, and narrowed toward a single idea: own the right to collect a slice of other companies’ drug sales, without running clinical trials yourself. Think of it as a toll road that charges every truck passing through, regardless of who built the truck. That model quietly compounded. Then, in July 2026, Ligand made the biggest bet of its modern life, and the latest quarterly filing shows what that bet is already producing, and what it cost.
The story, briefly
The filed numbers show royalty revenue growing 51% in a single quarter, powered by a major acquisition that closed mid-summer. The stock, sitting near $299, is priced at roughly 50 times earnings, well above its own decade-long average, meaning the market is paying a premium that assumes this growth rate is durable. The open question is whether a portfolio built largely through acquisition can keep compounding royalties fast enough to justify that premium, or whether the price already reflects the best of what is coming.
What the quarter actually shows
Two facts from the 10-Q filed October 30, 2026 sit uncomfortably next to each other. Total revenue fell sharply compared to the same quarter a year ago. Royalty revenue, the core of the business, rose 51%. Both are true simultaneously, and understanding why is the whole story of this quarter.
The drop in total revenue reflects a simple accounting fact: last year’s Q3 included a large one-time gain from selling an asset, income that does not repeat. Strip that away and the underlying business accelerated sharply. Royalties, the recurring toll-road payments from other companies selling drugs that use Ligand’s technology or assets, climbed to $70.3 million, representing nearly nine of every ten dollars the company collected. That is the number that matters for anyone thinking about whether this business compounds.
The engine behind that jump was the XOMA Royalty acquisition, completed July 14, 2026, for roughly $887 million, more than three years of Ligand’s own annual revenue. XOMA brought in seven commercial products already generating royalties, fourteen programs in late-stage clinical trials, and more than a hundred other assets. In the roughly two and a half months it was part of Ligand during Q3, it contributed meaningfully to revenue. A full quarter’s contribution is coming in Q4, which is why management raised its full-year adjusted earnings guidance, signaling confidence that royalties will be materially stronger in the final stretch of the year.
What the XOMA deal changed, permanently
Before XOMA, Ligand’s royalty portfolio was meaningful but concentrated. Filspari, a kidney disease drug from Travere Therapeutics, was a standout: per the Q3 2026 press release (investor.ligand.com, October 29, 2026), Filspari royalties grew 85% year-over-year in Q3. Strong, but a single product carrying that much weight is a risk. XOMA changed the geometry. The portfolio now spans over two hundred assets, including royalty streams from VABYSMO, an eye disease treatment, and MIPLYFFA, a rare neurological disease drug. Concentration risk did not disappear, but it shrank considerably.
Ligand also kept moving after the XOMA close. On September 22, 2026, it acquired a royalty interest in Santen’s Ryjunea, a pediatric myopia treatment, for $23 million upfront, securing tiered royalties on European sales. Two days later it committed additional capital to AvenCell Therapeutics, a CAR-T cell therapy company, in exchange for royalties on AvenCell’s pipeline. The pattern is consistent: Ligand deploys capital to buy future royalty streams before those drugs reach peak sales, betting that the drugs succeed and that the royalty percentage compounds into something large.
What is still being decided
The pipeline carries several near-term moments that will test whether the portfolio’s breadth translates into more royalty streams. Qtorin, a rapamycin formulation for a rare tissue condition, received FDA Priority Review with a decision expected February 28, 2027. Vibismo, which hit its Phase III target for a form of vision-threatening eye disease in July 2026, is on track for a potential regulatory filing in 2027. A Phase 2b readout for Velixibat in a liver disease is expected in early 2027. Ligand has said it anticipates up to seven pivotal readouts across its portfolio through 2027, a cadence that is either a diversified pipeline or a concentrated period of binary risk, depending on how those trials land.
The GAAP net loss in Q3 reflects the accounting cost of absorbing XOMA: amortization of acquired assets, financing charges, and deal expenses all flow through the income statement. The adjusted earnings figure, which strips those items out, is what management and most analysts are watching. That tension between GAAP and adjusted results is worth holding in mind: the adjusted number looks cleaner, but the acquisition debt is real and the amortization charges represent real economic dilution of the assets Ligand paid nearly $900 million to own.
The math and the mood
“The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently paying. At $299, our data puts Ligand’s price-to-earnings ratio at roughly 50 times, against its own decade median of about 33 times. Its price-to-sales ratio sits near the 96th percentile of its own history. The mood is generous. The math, based on filed results, shows a business genuinely accelerating, but one that just took on a debt load larger than several years of typical revenue to buy that acceleration. Those two readings are not necessarily incompatible, but the gap between them is wide enough that the next several quarters of royalty performance carry unusual weight.
Reading the numbers
- $70.3 million in Q3 royalty revenue, up 51% year-over-year. A royalty is a percentage of a drug’s sales paid to whoever owns the intellectual property or asset rights. Here it means Ligand collected $70.3 million simply because partner companies sold their drugs. A household analogy: imagine owning the right to 5% of a neighbor’s rental income. When they raise the rent and add two more properties, your check grows without you doing extra work. That is what happened here, amplified by XOMA.
- $887 million acquisition price for XOMA. To feel the scale: Ligand’s total revenue in all of FY2025 was $268 million. The company paid more than three years of its own revenue to buy XOMA’s royalty streams. Whether that price is justified depends entirely on how fast those royalties grow over the next decade.
- P/E of 50.4 vs. decade median of 32.7 (85th percentile), per our data. A price-to-earnings multiple is the price tag per dollar of annual profit: at 50 times, a buyer pays $50 for each $1 the company earns. Ligand’s own history says the market has typically paid about $33 for that same dollar. The current premium means the market expects earnings to grow fast enough to make today’s price look cheap in hindsight. If earnings growth slows, that premium compresses.
- Adjusted diluted EPS guidance raised to $9.50 to $9.75 for full-year 2026. Adjusted EPS strips out one-time acquisition costs and amortization charges. Think of it as the operating heartbeat of the business, before the accounting noise of deal-making. The raise signals management believes Q4 royalties, with a full quarter of XOMA, will be materially stronger than Q3.
Sources
- 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Ligand Q3 2026 press release (investor.ligand.com)
- Q3 2026 earnings call transcript (Seeking Alpha)
- Citigroup analyst valuation update, November 5, 2026 (MarketBeat)
- Stifel analyst valuation update, October 29, 2026 (Investing.com)
- OmniAb spin-off completion, November 2022 (investor.ligand.com)
- Q3 2026 results (GlobeNewswire)
